Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024

Background: Recombinant zoster vaccine (RZV), received its first marketing authorization in October 2017 to prevent herpes zoster and its complications in older adults. The purpose of this study was to provide comprehensively worldwide post-marketing safety information about RZV using data from the...

Full description

Saved in:
Bibliographic Details
Main Authors: Yamin Shu, Wenxin Cheng, Xucheng He, Liu Huang, Wei Chen, Qilin Zhang
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Preventive Medicine Reports
Subjects:
Vaccine safety
Post-marketing
Recombinant zoster vaccine
Adverse event
VAERS
Online Access:http://www.sciencedirect.com/science/article/pii/S2211335525000208
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items